Lv4
478 积分 2024-03-03 加入
A comprehensive review of immune checkpoint inhibitors for cancer treatment
9个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
9个月前
已完结
Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy
9个月前
已关闭
Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma
10个月前
已完结
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
10个月前
已完结
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade
10个月前
已完结
Immune Checkpoint Inhibitors — The Need for Innovation
10个月前
已完结
Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – A comprehensive cancer center experience
10个月前
已完结
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
10个月前
已完结
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
10个月前
已完结
皖公网安备34019202002308
